John Q Doyle

CEO John Q Doyle sold 16,656 shares of MRSH at $161.71 on 2026-06-02 via pre-arranged 10b5-1 plan; holds 116,811 non-derivative shares post-transaction.

President and CEO John Q Doyle executed a scheduled sale of 16,656 shares at $161.71 under a pre-arranged 10b5-1 trading plan on 2026-06-02, reducing his non-derivative holdings to 116,811 shares from 133,467 shares (-12.5%). The transaction is part of a predetermined plan rather than a discretionary decision, removing timing-based interpretation. The stock has since declined 18.6% from its 52-week high of $193.32 and is currently trading at $157.32, below the transaction price. While this marks a scheduled vest-and-sell action, Doyle retains 33,312 shares through stock options, maintaining meaningful economic exposure to the company. The company remains fundamentally healthy with $7.6B in quarterly revenue, $1.1B in net income, and a P/E of 19.30.

CEO John Q Doyle sold 16,655 MRSH shares at $183.30 on 2026-03-04 ($3.1M); holds 133,466 shares post-sale.

CEO Doyle sold 16,655 shares at $183.30, representing an 11.1% reduction in his holdings. His cross-ticker track record shows 4 prior open-market sales with an average 90-day return of -5.7% and a 75.00% well-timed rate, indicating historically strong timing on sell decisions. The stock is currently trading at $185.00, 2.5% below the 52-week high, and has declined 1.8% over the past 30 days. MRSH fundamentals show strong quarterly revenue of $6,351,000,000.00 with net income of $747,000,000.00 and annual revenue growth of 10.3%. This sale occurs in a stable operational context where the CEO maintains substantial holdings of 133,466 shares post-transaction.

MMC CEO Doyle sells 21,079 shares ($3.8M) via 10b5-1 plan; holds 87,681 shares post-sale

CEO John Q Doyle executed a 21,079-share sale of MMC at $182.22 on 2025-12-01 for $3,841,015.38, reducing his holdings from 108,760 shares to 87,681 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled and non-discretionary rather than a signal of changed executive sentiment. The sale represents a -19.4% reduction in his pre-transaction holdings, a material decrease in absolute position size, though the CEO retains substantial equity ownership. As a scheduled disposition under Rule 10b5-1, the transaction does not carry timing-based inference about near-term company outlook.

Marsh & McLennan CEO John Q Doyle sells 21,079 shares ($4.3M) under pre-arranged 10b5-1 plan

John Q Doyle, President and CEO of Marsh & McLennan Companies, sold 21,079 shares at $205.65 on 2025-09-02 for a total value of $4,334,896.35, reducing his holdings from 108,760 shares to 87,681 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance rather than a discretionary trade. The sale represents a 19.4% reduction in his pre-transaction holdings. Since this sale is governed by a 10b5-1 plan, it reflects a predetermined trading strategy rather than a response to current market conditions or company developments.

CEO Doyle sold 21,080 MMC shares at $232.05 ($4.9M); 19.4% reduction in holdings to 87,681 shares.

Doyle John Q, President and CEO of Marsh & McLennan, sold 21,080 shares for $4,891,614.00, reducing his holdings by 19.4% from 108,761 to 87,681 shares. The sale occurred at $232.05, below the current price of $234.86 and within recent trading range. Notably, his prior sell at MMC on 2025-03-03 posted a 90-day return of -1.4%, meaning the stock declined after that earlier sale. His cross-ticker track record shows 1 prior sell with a 90d well-timed rate of 100.00%, indicating a pattern of selling ahead of downturns. The company's fundamentals show solid performance with $7.1B in quarterly revenue, $1.4B net income, and 7.6% annual revenue growth, though the P/E of 28.64 reflects current market valuation.

CEO Doyle sells 21,080 shares of MMC for $5.0M at $237.05, retaining 87,681 shares

Doyle John Q, President and CEO of Marsh & McLennan Companies, sold 21,080 shares on March 3, 2025, at $237.05 per share, representing a -19.4% reduction in his pre-transaction holdings of 108,761 shares. The sale occurred near the 52-week high of $239.48, with the stock currently trading at $236.77. With a P/E of 26.84 and market cap of $116.3B, the company trades at a valuation premium to historical averages, though recent quarterly revenue of $5.7B and net income of $747.0M reflect solid near-term operational performance. The CEO retains substantial equity exposure (87.7K shares post-sale), suggesting continued alignment despite the material reduction in holdings.